Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.78 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12595743 | 0.88 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL8479743 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5765567 | 0.84 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL12595727 | 0.82 | LMNA (0.66) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL19293601 | 0.82 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL11005422 | 0.81 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL11736896 | 0.81 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL11626196 | 0.81 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL10761953 | 0.80 | PDE4B (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL21969548 | 0.80 | PDE3A (0.70) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | PDE4A 3343/4885PDE4B 2928/4885PDE4C 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.